Created by Steve Lehmann, director of venture operations at Portal Innovations, Stargaze is an artificial intelligence platform that maps the structure of biotechnology innovation and uses that knowledge to identify fruitful startups.
Steve Lehmann, director of venture operations at Portal Innovations, describes himself as a "startup midwife.” Prior to joining the VC firm, he led the George Shultz Innovation Fund at the University of Chicago, where he invested in academic spinouts.
“We create biotech infrastructure where none existed before,” Lehmann told In Vivo, outlining Portal Innovations’ strategy. This includes physical infrastructure,...
A positive mindset can boost exercise motivation. Learn how mental shifts help you start—and stick with—a healthier fitness routine.
Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma.
Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.
